432 related articles for article (PubMed ID: 23121690)
21. Anti-angiogenic therapies for malignant pleural mesothelioma.
Ceresoli GL; Zucali PA
Expert Opin Investig Drugs; 2012 Jun; 21(6):833-44. PubMed ID: 22519641
[TBL] [Abstract][Full Text] [Related]
22. Angiogenesis inhibitors in cancer therapy.
Dredge K; Dalgleish AG; Marriott JB
Curr Opin Investig Drugs; 2003 Jun; 4(6):667-74. PubMed ID: 12901224
[TBL] [Abstract][Full Text] [Related]
23. Anti-VEGF and beyond: shaping a new generation of anti-angiogenic therapies for cancer.
Bertolini F; Marighetti P; Martin-Padura I; Mancuso P; Hu-Lowe DD; Shaked Y; D'Onofrio A
Drug Discov Today; 2011 Dec; 16(23-24):1052-60. PubMed ID: 21875682
[TBL] [Abstract][Full Text] [Related]
24. Anti-angiogenesis therapy in cancer: current challenges and future perspectives.
Shojaei F
Cancer Lett; 2012 Jul; 320(2):130-7. PubMed ID: 22425960
[TBL] [Abstract][Full Text] [Related]
25. Molecular diagnosis of tumor angiogenesis and anti-angiogenic cancer therapy.
Sato Y
Int J Clin Oncol; 2003 Aug; 8(4):200-6. PubMed ID: 12955574
[TBL] [Abstract][Full Text] [Related]
26. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
Grothey A; Ellis LM
Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
[TBL] [Abstract][Full Text] [Related]
27. Design and development of polymer conjugates as anti-angiogenic agents.
Segal E; Satchi-Fainaro R
Adv Drug Deliv Rev; 2009 Nov; 61(13):1159-76. PubMed ID: 19699248
[TBL] [Abstract][Full Text] [Related]
28. [Role of angiogenesis in the growth and progression of tumors. Treatment with angiogenesis inhibitors: from promising results in experimental animal models to the reality of clinical use].
Plavetić ND; Letilović T; Vrbanec D
Lijec Vjesn; 2003; 125(9-10):260-5. PubMed ID: 15038217
[TBL] [Abstract][Full Text] [Related]
29. The VEGF/Rho GTPase signalling pathway: a promising target for anti-angiogenic/anti-invasion therapy.
van der Meel R; Symons MH; Kudernatsch R; Kok RJ; Schiffelers RM; Storm G; Gallagher WM; Byrne AT
Drug Discov Today; 2011 Mar; 16(5-6):219-28. PubMed ID: 21262381
[TBL] [Abstract][Full Text] [Related]
30. Anti-angiogenesis in cancer therapy: Hercules and hydra.
Bellou S; Pentheroudakis G; Murphy C; Fotsis T
Cancer Lett; 2013 Sep; 338(2):219-28. PubMed ID: 23707856
[TBL] [Abstract][Full Text] [Related]
31. Oncogenes and tumor angiogenesis: the question of vascular "supply" and vascular "demand".
Rak J; Yu JL
Semin Cancer Biol; 2004 Apr; 14(2):93-104. PubMed ID: 15018893
[TBL] [Abstract][Full Text] [Related]
32. Assessing the in vivo efficacy of biologic antiangiogenic therapies.
Wilson PM; LaBonte MJ; Lenz HJ
Cancer Chemother Pharmacol; 2013 Jan; 71(1):1-12. PubMed ID: 23053262
[TBL] [Abstract][Full Text] [Related]
33. Mechanisms of resistance to anti-angiogenesis therapies.
Giuliano S; Pagès G
Biochimie; 2013 Jun; 95(6):1110-9. PubMed ID: 23507428
[TBL] [Abstract][Full Text] [Related]
34. Therapeutic targets of multiple angiogenic factors for the treatment of cancer and metastasis.
Cao Y; Liu Q
Adv Cancer Res; 2007; 97():203-24. PubMed ID: 17419947
[TBL] [Abstract][Full Text] [Related]
35. Is copper chelation an effective anti-angiogenic strategy for cancer treatment?
Antoniades V; Sioga A; Dietrich EM; Meditskou S; Ekonomou L; Antoniades K
Med Hypotheses; 2013 Dec; 81(6):1159-63. PubMed ID: 24210000
[TBL] [Abstract][Full Text] [Related]
36. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies].
Cézé N; Lecomte T; Watier H
Med Sci (Paris); 2009 Dec; 25(12):1099-104. PubMed ID: 20035685
[TBL] [Abstract][Full Text] [Related]
37. Therapies using anti-angiogenic peptide mimetics of thrombospondin-1.
Henkin J; Volpert OV
Expert Opin Ther Targets; 2011 Dec; 15(12):1369-86. PubMed ID: 22136063
[TBL] [Abstract][Full Text] [Related]
38. Targeting angiogenesis in endometrial cancer - new agents for tailored treatments.
Papa A; Zaccarelli E; Caruso D; Vici P; Benedetti Panici P; Tomao F
Expert Opin Investig Drugs; 2016; 25(1):31-49. PubMed ID: 26560489
[TBL] [Abstract][Full Text] [Related]
39. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
[TBL] [Abstract][Full Text] [Related]
40. Broad targeting of angiogenesis for cancer prevention and therapy.
Wang Z; Dabrosin C; Yin X; Fuster MM; Arreola A; Rathmell WK; Generali D; Nagaraju GP; El-Rayes B; Ribatti D; Chen YC; Honoki K; Fujii H; Georgakilas AG; Nowsheen S; Amedei A; Niccolai E; Amin A; Ashraf SS; Helferich B; Yang X; Guha G; Bhakta D; Ciriolo MR; Aquilano K; Chen S; Halicka D; Mohammed SI; Azmi AS; Bilsland A; Keith WN; Jensen LD
Semin Cancer Biol; 2015 Dec; 35 Suppl(Suppl):S224-S243. PubMed ID: 25600295
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
